FDA Approves Auvelity for Agitation in Alzheimer’s Disease - Top-Institutions - MDSpire

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

  • By

  • Kathryn Wighton

  • April 30, 2026

  • 3 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Geriatric Psychiatry
    • Alzheimer's Disease Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Geriatrics
    • Neuropsychiatry

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Psychiatry
    • Alzheimer's Disease Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Psychiatry
    • Geriatrics

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Psychiatry
    • Alzheimer's Disease

Original Source(s)

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

  • by Kathryn Wighton

  • April 30, 2026

Related Content

An interpretable TimeMIL framework for fNIRS: differential diagnosis between schizophrenia and bipolar disorder

Side Effects: The Body Keeps Score

Turns out biology tracks more than we thought — from a spit test that reads your all-nighter to a surgical outcome that still shows up in household chores two decades later. Plus: habits aren't built gradually. They snap.

Consensus Guidance May Improve Sinonasal Mass Outcomes

Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.